BTK and acute myeloid leukemia: In addition, Igγ, Igμ, and Igα in AML-Ig from AML8 tended to use IGHV2-5/IGHD3-22/IGHJ3 (437/3709, 11.8%), IGHV3-74/IGHD2-15/IGHJ34 (219/523, 41.9%), and IGHV4-39/IGHD3-10/IGHJ4 (1197/4365, 27.4%), respectively (Figure 6B, right).